Gene expression studies have shown that in tumor with a mesenchymal signature (enriched with EMT-related gene signature) a decrease in the number of tumor infiltrating lymphocytes (TILs), accompanied by an increased expression of immunosuppressive cytokines (e.g., TGF-β and IL-10) and inhibitory immune check point molecules (CTL4, T-cell immunoglobulin, and TIM-3) is often observed (14). The gene discussed is IL10; the disease is neoplasm.